Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Overview of attention for article published in Cochrane database of systematic reviews, July 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

blogs: 1 blog
twitter: 10 X users

wikipedia: 2 Wikipedia pages
reddit: 2 Redditors

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 31 Mendeley

Summary Blogs X Wikipedia Reddit Dimensions citations

So far, Altmetric has seen 12 X posts from 10 X users, with an upper bound of 87,685 followers.

🧐Meilleure thérapie de première ligne pour les personnes atteintes d'un #CancerduPoumon non à petites cellules à un stade avancé avec un état de performance 2, sans mutation ciblée ou avec une mutation inconnue ➡️Revue @cochranecollab évaluant 22 essais 🔗h

18 Oct 2023

Reply Repost Favourite

RT @oncoblogger: Preferred chemotx for people with moderately performance status 2 with advanced #NSCLC and that have never received an…

16 Jul 2023

Reply Repost Favourite

RT @CochraneLibrary: JUST PUBLISHED - systematic review: 'Best therapy for people with advanced non‐small cell #LungCancer who have not bee…

12 Jul 2023

Reply Repost Favourite

RT @CochraneLibrary: JUST PUBLISHED - systematic review: 'Best therapy for people with advanced non‐small cell #LungCancer who have not bee…

12 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.